Patents by Inventor Mingzhen LI

Mingzhen LI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250007893
    Abstract: A secure transmission method and an apparatus are provided. The method includes: a first device encrypts a packet header of a to-be-sent packet including first data according to a transport layer security protocol to obtain an encrypted packet header. The first data is encrypted by an application layer security protocol. The first device sends a first encrypted packet to a second device. The first encrypted packet includes the encrypted packet header and the first data. According to this application, if the to-be-sent packet includes the first data encrypted by the application layer security protocol, when encrypting the to-be-sent packet according to the transport layer security protocol, the first device encrypts the packet header of the to-be-sent packet, but does not encrypt the first data. Accordingly, after receiving an encrypted packet, the second device does not need to decrypt the first data according to the transport layer security protocol.
    Type: Application
    Filed: July 1, 2024
    Publication date: January 2, 2025
    Inventors: Hongshan Tang, Ning Ma, Mingzhen Li, Chenyuan Fang
  • Patent number: 11673969
    Abstract: The present disclosure provides an anti-biotin antibody, and provides an amino acid sequence encoding the CDRs of the antibody. Studies have shown that the antibody only reacts with a biotin conjugate or derivative, and does not react with free biotin. The present disclosure further provides applications of the antibody in, including but not limited to, ELISA, cell capture, sorting and enrichment, western blotting, flow cytometry, immunocytofluorescent staining, and immunohistochemistry. The anti-biotin antibody conjugated immunomagnetic beads can specifically and directly recognize a biotin labeled antigen, and do not bind to free biotin which is often presented in clinical samples and culture media. In addition, the anti-biotin antibody-conjugated magnetic beads or anti-biotin antibody-fluorescein provide an ideal solution for the isolation of specific cells, and can even enrich and separate target cells from samples rich in debris or other rare biological materials.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: June 13, 2023
    Assignee: HANGZHOU BIOLYNX TECHNOLOGY CO., LTD.
    Inventors: Mingzhen Li, Li Pan, Min Hu, Hao Liu
  • Publication number: 20220041755
    Abstract: The present disclosure provides an anti-biotin antibody, and provides an amino acid sequence encoding the CDRs of the antibody. Studies have shown that the antibody only reacts with a biotin conjugate or derivative, and does not react with free biotin. The present disclosure further provides applications of the antibody in, including but not limited to, ELISA, cell capture, sorting and enrichment, western blotting, flow cytometry, immunocytofluorescent staining, and immunohistochemistry. The anti-biotin antibody conjugated immunomagnetic beads can specifically and directly recognize a biotin labeled antigen, and do not bind to free biotin which is often presented in clinical samples and culture media. In addition, the anti-biotin antibody-conjugated magnetic beads or anti-biotin antibody-fluorescein provide an ideal solution for the isolation of specific cells, and can even enrich and separate target cells from samples rich in debris or other rare biological materials.
    Type: Application
    Filed: September 4, 2020
    Publication date: February 10, 2022
    Inventors: Mingzhen LI, Li PAN, Min HU, Hao LIU
  • Patent number: 10960082
    Abstract: Disclosed are a type of tridentate linkers and use thereof. The tridentate linkers can be used to prepare an antibody drug conjugates as represented by formula I, L-(T-A-D)n??I wherein, L is an antibody, antibody fragment or protein; T is a tridentate linker part; A is a cleavable linker group or a noncleavable linker part; D is a drug part; n is an integer of 0-8. The structure of the tridentate linker part is as represented by formula II, wherein, W is substituted aryl, heteroaryl, linear alkyl, cycloalkyl, heterocycloalkyl, or any combination thereof.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: March 30, 2021
    Assignee: NEWBIO THERAPEUTICS, INC.
    Inventors: Deqiang An, Nianhe Han, Di Zeng, Hang Yang, Peng Zhu, Mingzhen Li, Li Jian, Chun Yang
  • Publication number: 20160015832
    Abstract: Disclosed are a type of tridentate linkers and use thereof. The tridentate linkers can be used to prepare an antibody drug conjugates as represented by formula I, L-(T-A-D)n ??I wherein, L is an antibody, antibody fragment or protein; T is a tridentate linker part; A is a cleavable linker group or a noncleavable linker part; D is a drug part; n is an integer of 0-8. The structure of the tridentate linker part is as represented by formula II. wherein, W is substituted aryl, heteroaryl, linear alkyl, cycloalkyl, heterocycloalkyl, or any combination thereof.
    Type: Application
    Filed: July 23, 2015
    Publication date: January 21, 2016
    Applicant: NEWBIO THERAPEUTICS, INC.
    Inventors: Deqiang AN, Nianhe HAN, Di ZENG, Hang YANG, Peng ZHU, Mingzhen LI, Li JIAN, Chun YANG